Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

430 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
Halozyme Therapeutics : Investor Update
PU
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
PR
Transcript : Halozyme Therapeutics, Inc., 2024 Guidance/Update Call, Jun 06, 2024
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
PR
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR
Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR
Mahesh Krishnan Elected to Halozyme's Board of Directors
PR
Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Transcript : Halozyme Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM
Halozyme to Participate in Upcoming Investor Conferences
PR
Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
PR
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy
AQ
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR
Halozyme Announces argenx Received Approval in Japan for VYVDURA Co-Formulated with ENHANZE for Generalized Myasthenia Gravis
AQ
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
PR
Transcript : Halozyme Therapeutics, Inc. - Special Call
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
PR
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
AQ
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
PR
Halozyme to Present at Upcoming Investor Conferences
PR
Halozyme Announces argenx Receives European Commission Approval of VYVGART SC with ENHANZE for Generalized Myasthenia Gravis
AQ
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
PR
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE Technology in Alzheimer's disease
AQ
Transcript : Halozyme Therapeutics, Inc., Q3 2023 Earnings Call, Nov 06, 2023
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
PR
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
PR
Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
PR
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
PR
Transcript : Halozyme Therapeutics, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 10:50 AM
Halozyme to Present at Upcoming Investor Conferences
PR
Halozyme Announces Approval of Roche's Tecentriq Subcutaneous with ENHANZE in Great Britain
AQ
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
PR
Transcript : Halozyme Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR
Drugmakers go under the skin, skirting early US Medicare price negotiations
RE
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART Hytrulo with Halozyme's ENHANZE Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
AQ
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
PR
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS with Halozyme's ENHANZE Drug Delivery Technology in Patients with Multiple Sclerosis
AQ
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
PR
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
PR
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 08:00 AM
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR
Transcript : Halozyme Therapeutics, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 04:20 PM
Halozyme Seeks M&A Opportunities
CI
Transcript : Halozyme Therapeutics, Inc., Q1 2023 Earnings Call, May 09, 2023
No results for this search
  1. Stock Market
  2. Advanced search
  3. Helen Torley
  4. News